Market Closed

ALT
Altimmune
$ 1.65
2.48%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

Altimmune News

Latest Altimmune Stock News & ALT Headlines

ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns
2 days ago | zacks.com
Altimmune: Still Too Late And Too Capital-Intensive
2 days ago | seekingalpha.com
Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript
3 days ago | seekingalpha.com
What Altimmune (ALT) Said on Its Q3 Earnings Call
3 days ago | marketbeat.com
Altimmune Announces Third Quarter 2026 Financial Results and Business Update
3 days ago | globenewswire.com
Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology
3 days ago | globenewswire.com
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
6 days ago | globenewswire.com
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
10 days ago | globenewswire.com
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
10 days ago | globenewswire.com
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
19 days ago | globenewswire.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

ALT
Altimmune
$ 1.65
2.48%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago